What is HC Wainwright’s Estimate for ALGS Q1 Earnings?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Aligos Therapeutics in a report issued on Wednesday, April 15th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($1.27) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2027 earnings at ($1.29) EPS, Q3 2027 earnings at ($0.84) EPS and Q4 2027 earnings at ($0.85) EPS.

Other analysts have also recently issued research reports about the company. Westpark Capital began coverage on Aligos Therapeutics in a research report on Thursday, March 26th. They issued a “buy” rating and a $48.00 price target for the company. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. UBS Group began coverage on Aligos Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Wall Street Zen cut Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Aligos Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $41.50.

Aligos Therapeutics Price Performance

Shares of NASDAQ:ALGS opened at $6.68 on Friday. Aligos Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $13.69. The business has a 50-day moving average of $7.27 and a two-hundred day moving average of $8.50. The stock has a market capitalization of $41.35 million, a P/E ratio of -0.78 and a beta of 2.62.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%.The company had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.27 million.

Hedge Funds Weigh In On Aligos Therapeutics

Several large investors have recently made changes to their positions in ALGS. Woodline Partners LP acquired a new position in shares of Aligos Therapeutics during the 1st quarter worth about $2,602,000. Geode Capital Management LLC lifted its position in shares of Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after purchasing an additional 5,978 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Aligos Therapeutics during the 2nd quarter worth about $100,000. NorthCrest Asset Manangement LLC acquired a new position in shares of Aligos Therapeutics during the 3rd quarter worth about $98,000. Finally, Vanguard Group Inc. lifted its position in shares of Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after purchasing an additional 31,913 shares during the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

Key Aligos Therapeutics News

Here are the key news stories impacting Aligos Therapeutics this week:

• Positive Sentiment: Aligos signed an exclusive license with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium in Greater China (Mainland China, Taiwan, Hong Kong, Macau). The deal gives Aligos a regional commercialization partner and could provide non-dilutive development funding and future milestone/royalty streams if terms and milestones are paid. GlobeNewswire release
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $50 price target on ALGS while publishing multi-quarter EPS estimates for FY2027 — a bullish institutional signal that can attract growth-oriented investors despite the company’s current losses. MarketBeat / HC Wainwright note
• Neutral Sentiment: Widespread media coverage (Investing.com, ThePharmaLetter, Yahoo Finance, MSN and regional press) is amplifying awareness of the China licensing deal — this can increase short-term trading interest and volatility but does not by itself change fundamentals. Investing.com coverage
• Negative Sentiment: Despite the licensing announcement and analyst attention, ALGS faces clear headwinds: very small market capitalization, deeply negative earnings and margins, and historically volatile trading/low average volume — factors that can lead investors to sell into short-term news or impose a steep risk premium on the shares. MarketBeat data

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.